Common TitleHCV Target: Renal Disease
Official Title Safety and Efficacy of Sofosbuvir-Containing Regimens in Hepatitis C-Infected Patients with Impaired Renal Function
Purpose / DescriptionIn the HCV TARGET trial, investigators reported findings from a longitudinal cohort study of HCV treatment of 1893 patients, including patients renal disease, using one of four sofosbuvir-containing regimens: (1) sofosbuvir plus peginterferon plus ribavirin, (2) sofosbuvir plus ribavirin, (3) sofosbuvir plus simeprevir, and (4) sofosbuvir plus simeprevir plus ribavirin. Overall, the SVR12 rates were high (81 to 89%) across different levels of baseline renal insufficiency, with the one exception that cirrhotic patients with estimated GFR less than 30 mL/min/1.73m2 had significantly lower SVR12 rates. In addition, the rate of treatment-related anemia was higher in patients with more advanced renal disease.
ClinicalTrials.gov NCT01474811
Treatments
Sofosbuvir

Sofosbuvir
Tradename:SovaldiOther Names:SOFClass:FDA-ApprovedFunding
Non-IndustryUniversity of Florida and University of North Carolina